- Home
- EDIT vs NCZ Comparison
EDIT vs NCZ Comparison
Compare EDIT & NCZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDIT
- NCZ
- Stock Information
- Founded
- EDIT 2013
- NCZ 2003
- Country
- EDIT United States
- NCZ United States
- Employees
- EDIT N/A
- NCZ N/A
- Industry
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- NCZ Finance Companies
- Sector
- EDIT Health Care
- NCZ Finance
- Exchange
- EDIT Nasdaq
- NCZ Nasdaq
- Market Cap
- EDIT 263.7M
- NCZ 228.3M
- IPO Year
- EDIT 2016
- NCZ N/A
- Fundamental
- Price
- EDIT $2.28
- NCZ $13.21
- Analyst Decision
- EDIT Buy
- NCZ
- Analyst Count
- EDIT 12
- NCZ 0
- Target Price
- EDIT $6.20
- NCZ N/A
- AVG Volume (30 Days)
- EDIT 2.2M
- NCZ 533.0K
- Earning Date
- EDIT 08-19-2025
- NCZ 01-01-0001
- Dividend Yield
- EDIT N/A
- NCZ 12.16%
- EPS Growth
- EDIT N/A
- NCZ N/A
- EPS
- EDIT N/A
- NCZ N/A
- Revenue
- EDIT $35,837,000.00
- NCZ N/A
- Revenue This Year
- EDIT N/A
- NCZ N/A
- Revenue Next Year
- EDIT N/A
- NCZ N/A
- P/E Ratio
- EDIT N/A
- NCZ N/A
- Revenue Growth
- EDIT N/A
- NCZ N/A
- 52 Week Low
- EDIT $0.91
- NCZ $2.50
- 52 Week High
- EDIT $4.90
- NCZ $3.15
- Technical
- Relative Strength Index (RSI)
- EDIT 43.28
- NCZ 66.81
- Support Level
- EDIT $2.37
- NCZ $13.01
- Resistance Level
- EDIT $2.67
- NCZ $13.19
- Average True Range (ATR)
- EDIT 0.23
- NCZ 0.11
- MACD
- EDIT -0.08
- NCZ -0.00
- Stochastic Oscillator
- EDIT 5.37
- NCZ 97.22
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
About NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.